Showing results (251-260 of 432) with videos related to
Sort By:
Pageof 44
BMJ Open|July 24, 2021
Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database studyEmilio Ortega, Rosa Corcoy, Mònica Gratacòs, et al.Antimicrobial Agents and Chemotherapy|April 18, 2018
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho SystemRicardo Moure, Pere Domingo, Joan Villarroya, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.Antiviral Therapy|July 19, 2012
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune functionArkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.Plos One|September 9, 2017
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approachMar Masiá, Sergio Padilla, Santiago Moreno, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2009
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006Santiago Pérez Cachafeiro, Julia Del Amo, Jose A Iribarren, et al.Plos One|August 8, 2013
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory studyJosé R Santos, José A Muñoz-Moreno, José Moltó, et al.Cardiovascular Diabetology|October 19, 2022
The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19)Gemma Llauradó, Bogdan Vlacho, Matthieu Wargny, et al.Frontiers in Immunology|August 4, 2018
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy InitiationIsaac Rosado-Sánchez, Inés Herrero-Fernández, Miguel Genebat, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2008
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903Juan Berenguer, Juan González, Esteban Ribera, et al.Pageof 44